


The EUCAST steering committee

- Chairman Gunnar Kahlmeter(2005)
- Scientific secretary, Derek Brown (2005)
- BSAC (The UK), Alasdair MacGowan (2005)
- CA-SFM (France), Fred Goldstein (2005)
- CRG (The Netherlands) Johan W. Mouton (2005)
- DIN (Germany), Arne Rodloff (2005)
- NWGA (Norway), Martin Steinbakk (2005)
- SRGA (Sweden), Anders Österlund (2005)
- EUCAST rep 1, Pavla Urbaskova (Czech Republic), (2004)
- EUCAST rep 2, Alkiviadis Vatopoulos (Greece), (2005)



EUCAST steering committee at work, 2003

From the EUCAST new software "Antimicrobial wild type distributions - a reference database:



The EUCAST General Committee

- Austria Prof Helmut Mittermayer
- Belgium Prof Jan Verhaegen
- Bosnia Dr Selma Uzunovic-Kamberovic
- Bulgaria Prof Krassimir Melodiev
- Croatia Dr Arjana Tambic-Andrejevic
- Czech Republic Dr Pavla Urbaskova
- Denmark Dr Niels Frimodt-Møller
- Estonia Dr Paul Naaber
- Finland Dr Antti Naarala
- France Dr Fred W. Goldstein
- Germany Prof Bernd Wiedemann
- Greece Prof Alkiviadis Vatopoulos
- Hungary Dr Éva Bán
- Iceland Dr Karl Gustaf Kristinnsson
- Ireland Dr Martin Cormican
- Italy Prof Enrico Magliano
- Lithuania Prof Arvydas Ambrozaitis
- Netherlands Prof John Degener
- Norway Dr Martin Steinbakk
- Poland Prof Wioletta Hryniewicz
- Portugal Prof Jose Melo Cifriano
- Romania no official representative
- Russia Prof Sergei Sidorenko
- Serbia Dr Lazar Ranin
- Slovak Republic Prof. Milan Niks
- Slovenia Dr Jana Kolman
- Spain Dr Francisco Soriano
- Sweden Dr Barbro Olsson-Liljequist
- Switzerland Prof Jacques Bille
- Turkey Dr Deniz Gür
- UK Prof Richard Wise
- Yugoslavia not confirmed
- Pharmaceutical Industry Representatives Prof. André Bryskier, Hoechst Marion Roussel
- Rep 2 not nominated
- Device Manufacturers Representatives Dr. Jean-Pierre Marcel, bioMérieux*
- Ms. Maureen Mansfield, TREK*
- Mr. Daniel Malait, Bio-Rad*
- Mr. Ivo Steenackers, Becton-Dickinson*

Appointments by ESCMID

- chairholder and scientific secretary (3 years)
- national breakpoint committee seats on the steering committee (3 years)
- 2 representatives from the EUCAST general committee from countries not otherwise represented on the steering committee (2 years).

Appointments by the European countries

- appoint one representative each to serve for 2 years (new or confirmed appointments 2004)
- apply to the ESCMID board for a position on the steering committee (active national committees, ie committees with >2 meetings per year are eligible)

EUCAST websites

- <http://www.eucast.org>
- EUCAST web-site for wild type distributions, breakpoints and epidemiological cut-off values (soon available to all – see table and graph).

During 2002 the EUCAST steering committee have made the following tentative decisions:

- a common expression for SIR-classification: $S \leq$ and $R >$
- a common MIC microbroth dilution method as the reference method (a common MIC agar dilution method has already been described)
- a process for setting breakpoints for new antibiotics (tryouts: daptomycin, garenoxacin – both companies contacted)
- a process for harmonising breakpoints for existing antibiotics (fluoroquinolones are almost done; aminoglycosides, glycopeptides and linezolid are next)
- new definitions for clinical breakpoints
- new definitions for wild type bacteria and epidemiological cut-off values

EUCAST symposium: Harmonization of quinolone breakpoints in Europe (May 12th, 10.00 -12.00, Hall 1)

- Chairpersons:** Dr Martin Steinbakk (Norway) Dr Fred Goldstein (France)
1. Current breakpoints and the EUCAST approach to harmonization of breakpoints - Dr Derek Brown (UK) (10 min)
 2. EMEA view on the harmonization of European breakpoints - Dr Bo Aronsson (London, UK) (15 min)
 3. Epidemiological cut off values based on wild type MIC distributions - Dr Gunnar Kahlmeter (Sweden) (15 min)
 4. Pharmacodynamic approach and Monte Carlo simulation in establishing breakpoints Dr Johan W. Mouton (Netherlands) (15 min)
 5. Tentative harmonized breakpoints for quinolones - Dr Gunnar Kahlmeter (Vaxjö, Sweden) (10 min)
 6. General discussion (30 min)

The symposium is immediately followed by an open EUCAST business meeting 12.15 - 13.30.

Questions on EUCAST? Visit the website www.eucast.org or e-mail gunnar.kahlmeter@tkronoberg.se or dfjb2@cam.ac.uk

EUCAST publications

1. European Committee on Antimicrobial Susceptibility Testing. (2000). Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. EUCAST Definitive Document E.Def 1.2. *Clinical Microbiology and Infection* 6, 503-8.
2. European Committee on Antimicrobial Susceptibility Testing. (2000). Determination of antimicrobial susceptibility test breakpoints. EUCAST Definitive Document E.Def 2.1. *Clinical Microbiology and Infection* 6, 570-2.
3. European Committee on Antimicrobial Susceptibility Testing. (2000). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. EUCAST Definitive Document E.Def 3.1. *Clinical Microbiology and Infection* 6, 509-15.
4. European Committee on Antimicrobial Susceptibility Testing. (2001). Linezolid breakpoints. EUCAST Definitive Document E.Def 4.1. *Clinical Microbiology and Infection* 7, 283-4.
5. European Committee on Antimicrobial Susceptibility Testing. (In press). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth microdilution. EUCAST Discussion Document E.Dis 5.1. *Clinical Microbiology and Infection*.
6. Ridgway, G.L., Bébéc, C., Bébéc, C.M, Felmingham, D., Maurin, M., Pechère, J.C. et al. (2001). Antimicrobial susceptibility testing of intracellular and cell-associated pathogens. EUCAST Discussion Document E.Dis 6.1. *Clinical Microbiology and Infection* 7 (issue 12 insert), 1-10.
7. Rodríguez-Tudela, J.L., Barchiesi, F., Bille, J., Chrystanthou, E., Cuenca-Estrella, M., Deming, D. et al. (In press). Determination of minimum inhibitory concentrations by broth microdilution of fermentative yeasts. EUCAST Discussion Document E.Dis 7.1. *Clinical Microbiology and Infection*.
8. Drobniewski, F. (2002). Antimicrobial susceptibility testing of *Mycobacterium tuberculosis*. EUCAST Discussion Document E.Dis 8.1. *Clinical Microbiology and Infection* 8 (issue 10 insert), 1-10.

The EUCAST General Committee

Austria	Prof Helmut Mittermayer
Belgium	Prof Jan Verhaegen
Bosnia	Dr Selma Uzunovic-Kamberovic
Bulgaria	Prof Krassimir Metodiev
Croatia	Dr Arjana Tambic-Andrasevic
Czech Republic	Dr Pavla Urbaskova
Denmark	Dr Niels Frimodt-Møller
Estonia	Dr Paul Naaber
Finland	Dr Antti Nissinen
France	Dr Fred W. Goldstein
Germany	Prof Bernd Wiedemann
Greece	Prof Alkiviadis Vatopoulos
Hungary	Dr Éva Bán
Iceland	Dr Karl Gustaf Kristinnson
Ireland	Dr Martin Cormican
Italy	Prof Enrico Magliano
Lithuania	Prof Arvydas Ambrozaitis
Netherlands	Prof John Degener
Norway	Dr Martin Steinbakk
Poland	Prof Waleria Hryniewicz
Portugal	Prof Jose Melo Cristino
Romania	no official representative
Russia	Prof Sergei Sidorenko
Serbia	Dr Lazar Ranin
Slovak Republic	Prof. Milan Niks
Slovenia	Dr Jana Kolman
Spain	Dr Francisco Soriano
Sweden	Dr Barbro Olsson-Liljequist
Switzerland	Prof Jaques Bille
Turkey	Dr Deniz Gür
UK	Prof Richard Wise
Yugoslavia	not confirmed

Pharmaceutical Industry Representatives

Prof. André Bryskier, Hoechst Marion Roussel
Rep 2 not nominated

Device Manufacturers Representatives

Dr Jean-Pierre Marcel, bioMérieux*
Ms Maureen Mansfield, TREK*
Mr Daniel Malait, Bio-Rad*
Mr Ivo Steenackers, Becton-Dickinson*
*STMA (Susceptibility Testing Manufacturers Association)

EUCAST structure

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is a standing ESCMID committee. It was formed in 1996 and restructured at ECCMID in Milan 2002 and consists of a General Committee with representatives from all European countries, from the pharmaceutical industry, and from in vitro media and device industries. EUCAST is led by an ESCMID-appointed Steering Committee, which consists of a Chairman, a Scientific Secretary, and six National Breakpoint Committee representatives as well as by two representatives of the EUCAST General Committee (see EUCAST Organisation). Decisions are made by the Steering Committee after consultation with the General Committee.

EUCAST objectives

EUCAST was set up to standardise susceptibility testing in Europe so that comparable results and interpretations are produced.

Appointments by ESCMID

- chairholder and scientific secretary (3 years)
- national breakpoint committee seats on the steering committee (3 years)
- 2 representatives from the EUCAST general committee from countries not otherwise represented on the steering committee (2 years).

Appointments by the European countries

- appoint one representative each to serve for 2 years (new or confirmed appointments 2004)
- apply to the ESCMID board for a position on the steering committee (active national committees, ie committees with >2 meetings per year are eligible)

EUCAST websites

- <http://www.eucast.org>
- EUCAST web-site for wild type distributions, breakpoints and epidemiological cut-off values (soon available to all – see table and graph).

During 2002/3 the EUCAST steering committee have made the following tentative decisions:

- a common expression for SIR-classification: S_≤ and R_>
- a common MIC microbroth dilution method as the referenc method (a common MIC agar dilution method has already been described)
- a process for setting breakpoints for new antibiotics (tryouts: daptomycin, garenoxacin – both companies contacted)
- a process for harmonising breakpoints for existing antibiotics (fluoroquinolones are almost done; aminoglycosides, glycopeptides and linezolid are next)
- new definitions for clinical breakpoints
- new definitions for wild type bacteria and epidemiological cut-off values

The EUCAST steering committee

Chairman Gunnar Kahlmeter(2005)

Scientific secretary, Derek Brown (2005)

BSAC (The UK), Alasdair MacGowan (2005)

CA-SFM (France), Fred Goldstein (2005)

CRG (The Netherlands) Johan W. Mouton (2005)

DIN (Germany), Arne Rodloff (2005)

NWGA (Norway), Martin Steinbakk (2005)

SRGA (sweden), Anders Österlund (2005)


EUCAST rep 1, Pavla Urbaskova (Czech Republic), (2004)

EUCAST rep 2, Alkiviadis Vatopoulos (Greece), (2004)



EUCAST Steering Committee, 2003


From the EUCAST new software "Antimicrobial wild type distributions - a reference database:



EUCAST publications

1. European Committee on Antimicrobial Susceptibility Testing. (2000). Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. EUCAST Definitive Document E.Def 1.2. *Clinical Microbiology and Infection* 6, 503-8.
2. European Committee on Antimicrobial Susceptibility Testing. (2000). Determination of antimicrobial susceptibility test breakpoints. EUCAST Definitive Document E.Def 2.1. *Clinical Microbiology and Infection* 6, 570-2.
3. European Committee on Antimicrobial Susceptibility Testing. (2000). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. EUCAST Definitive Document E.Def 3.1. *Clinical Microbiology and Infection* 6, 509-15.
4. European Committee on Antimicrobial Susceptibility Testing. (2001). Linezolid breakpoints. EUCAST Definitive Document E.Def 4.1. *Clinical Microbiology and Infection* 7, 283-4.
5. European Committee on Antimicrobial Susceptibility Testing. (In press). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth microdilution. EUCAST Discussion Document E.Def 5.1. *Clinical Microbiology and Infection*.
6. Ridgway, G.L., Bèbèar, C., Bèbèar, C.M., Felmingham, D., Maurin, M., Pechère, J.C. et al. (2001). Antimicrobial susceptibility testing of intracellular and cell-associated pathogens. EUCAST Discussion Document E.Dis 6.1. *Clinical Microbiology and Infection* 7 (issue 12 insert), 1-10.
7. Rodríguez-Tudela, J.L., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca-Estrella, M., Desjard, D. et al. (in press). Determination of minimum inhibitory concentrations by broth microdilution of fermentative yeasts. EUCAST Discussion Document E.Dis 7.1. *Clinical Microbiology and Infection*.
8. Drobniewski, F. (2002). Antimicrobial susceptibility testing of Mycobacterium tuberculosis. EUCAST Discussion Document E.Dis 8.1. *Clinical Microbiology and Infection* 8 (issue 10 insert), 1-10.

Questions on EUCAST? Visit the website www.eucast.org or e-mail gunnar.kahlmeter@tkronoberg.se or dfjb2@cam.ac.uk



Aggregated ciprofloxacin/E.coli MIC-distributions from 6 separate data sources (national breakpoint committees, Antimicrobial resistance surveillance programs, EARSS, drug company data etc).